<DOC>
	<DOCNO>NCT00617656</DOCNO>
	<brief_summary>Primary objective : · Time progression . Secondary objective : - Assess Overall survival treatment group . - Assess Tumor response rate use RECIST criterion - Assess Toxicity profile patient enrol study . - Exploratory evaluation potential genetic marker response resistance chemotherapy .</brief_summary>
	<brief_title>Multicenter , Predictive , Prospective , Phase III , Open , Randomized , Pharmacogenomic Study Patients With Advanced Lung Carcinoma</brief_title>
	<detailed_description>Study population : Patients advance non-small-cell lung cancer receive treatment disease stage good performance status ( ECOG 0-1 ) measurable disease ( least one target lesion accord RECIST criterion ) . Duration treatment : Six chemotherapy cycle give . The duration every cycle 21 day . If treatment beneficial , may prolong total 8 cycle discretion investigator . Calendar plan finalization date : The approximate duration study 3 year recruitment follow 1 year follow-up .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Patients age 18 year . 2 . Histologically confirm diagnosis nonsmallcell lung carcinoma . 3 . Only patient advance disease define stage IV IIIB without pleural effusion include . In event IIIB disease without pleural effusion patient , reason ( respiratory disease , large radiation volume ... ) may candidate chemotherapy radiotherapy treatment may treat chemotherapy , consider . 4 . Tumor specimen available ( accord criterion specimenprocessing laboratory ) analysis RAP80 BRCA1 expression mRNA . 5 . A measurable lesion , define RECIST criterion . 6 . Karnofsky score 80 % ( ECOG &lt; 2 ) . 7 . No previous treatment chemotherapy agent disseminate disease . Chemotherapy allow patient 's initial diagnosis limit disease patient receive adjuvant neoadjuvant treatment , long minimum 6 month pass since end adjuvant and/or neoadjuvant chemotherapy . 8 . Patients cerebral disease may include without time limitation holocranial irradiation complementary antiedema treatment , long correct control clinical symptom arise brain disease symptomatic . 9 . Patients follow hematologic value : ANC ≥ 1.5 x 109/L Hb ≥ 10 g/dl Platelets ≥ 100 x 109/L 10 . Patients follow biochemical value : Bilirubin ≤ 1.5 mg/dL AST ALT &lt; 1.5 upper limit normality Creatinine clearance ≥ 60 ml/min . 11 . Patients childbearing age either sex must use effective contraceptive method ( barrier method birth control method ) enter study participate study . 12 . Patients sign inform consent form inclusion study specifies clinical trial treatment entails consent analysis biological specimen tumor blood . 13 . Patients must available clinical followup . EXCLUSION CRITERIA 1 . Previous chemotherapy treatment , except supposition reflect inclusion criterion 7 . 2 . Patients diagnose another neoplasm , exception cervical carcinoma situ , treat squamous cell carcinomas superficial bladder tumor ( Ta TIS ) , malignant tumor receive curative treatment within last 5 year inclusion study . 3 . Patients serious active bacterial fungal infective process clinical vantage point ( = grade 2 NCICTC , Version 3 ) . 4 . Patients receive investigational medicinal product 21 day inclusion study . 5 . Patients HIV infection , HCV infection , coronary artery disease uncontrolled arrhythmia , uncontrolled cerebrovascular disease , clinical condition , judgment investigator , contraindicate patient 's participation study . 6 . Patients pregnant breastfeeding . Women childbearing age must negative pregnancy test perform within 7 day onset treatment . 7 . Substance abuse clinical , psychological social condition undermine validity inform consent protocol compliance . 8 . Patients present contraindication suspect allergy product investigation study 9 . Impossibility comply chemotherapy treatment due cultural geographic circumstance . 10 . Significant weight loss ( = 10 % body weight ) 6 week inclusion study . 11 . Any condition unstable could endanger patient 's safety and/or patient 's compliance study . 12 . Contraindication steroid use .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>LUNG CANCER</keyword>
</DOC>